AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17767063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy group (diet control combined with aerobic exercises)
Number of subjects: 60
Study 17767063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (30 minutes, 3-5 times per week for 12 weeks)
Number of subjects: 60
Study 17767063 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 60
Study 10394257 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of bisoprolol
Number of subjects: 54
Study 10394257 — intervention group
Group type: COMPARATOR
Intervention: 240 mg of verapamil LP
Number of subjects: 54
Study 8893576 — intervention group
Group type: EXPERIMENTAL
Intervention: FUT‐175 (10 mg/L) during CPB
Number of subjects: 45
Study 8893576 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB sets (C)
Number of subjects: 45
Study 8893576 — intervention group
Group type: COMPARATOR
Intervention: Biocompatible CPB sets (B)
Number of subjects: 45
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stimuli (100‐ms, 1000 Hz, 90dB sinusoidal tone bursts)
Number of subjects: 0
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency deviant (1500 Hz)
Number of subjects: 0
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity deviant (67dB SPL)
Number of subjects: 0
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration deviant (50 ms)
Number of subjects: 0
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: N100m to standards and deviants
Number of subjects: 0
Study 1886961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch fields
Number of subjects: 0
Study 6350625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (0.5 gm. intramuscularly every 12 hours)
Number of subjects: 51
Study 6350625 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (1 mg. per kg. intramuscularly every 8 hours)
Number of subjects: 51
Study 30463425 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC)
Number of subjects: 328
Study 30463425 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 328
Study 29602567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral keratoconjunctivitis (specifically adenovirus D species)
Number of subjects: 500
Study 29602567 — intervention group
Group type: COMPARATOR
Intervention: Adenoviral keratoconjunctivitis (non-adenovirus D species)
Number of subjects: 500
Study 29602567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral keratoconjunctivitis (all participants)
Number of subjects: 500
Study 29602567 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoviral D species
Number of subjects: 500
Study 29602567 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-United States origin participants
Number of subjects: 500
Study 26912213 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpiperazine (BZP) 200 mg
Number of subjects: 11
Study 26912213 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX) 20 mg
Number of subjects: 11
Study 26912213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24561644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane, Desflurane, Isoflurane
Number of subjects: 59
Study 24561644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 59
Study 22115971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation program (MBSR)
Number of subjects: 300
Study 22115971 — intervention group
Group type: COMPARATOR
Intervention: 10 Keys to Healthy Aging (control)
Number of subjects: 300
Study 19515181 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg + Metformin 500 mg
Number of subjects: 1306
Study 19515181 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 10 mg + Metformin 500 mg
Number of subjects: 1306
Study 19515181 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin 10 mg
Number of subjects: 1306
Study 19515181 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg
Number of subjects: 1306
Study 17893379 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour intensive education for physicians
Number of subjects: 102
Study 17893379 — intervention group
Group type: COMPARATOR
Intervention: 2-hour traditional education for physicians
Number of subjects: 102
Study 15545304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (selective dopamine-1 receptor agonist)
Number of subjects: 0
Study 11751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (od) vancomycin
Number of subjects: 121
Study 11751780 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily (bd) vancomycin
Number of subjects: 121
Study 9679994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision aid (booklet and audiotape)
Number of subjects: 0
Study 9679994 — intervention group
Group type: COMPARATOR
Intervention: General educational pamphlet
Number of subjects: 0
Study 8082348 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose bolus alteplase (n = 96)
Number of subjects: 140
Study 8082348 — intervention group
Group type: COMPARATOR
Intervention: Full dose 100 mg/2 h alteplase (n = 44)
Number of subjects: 140
Study 2530542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg b.d.
Number of subjects: 135
Study 2530542 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.d.
Number of subjects: 135
Study 31885300 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole combined with debridement gel
Number of subjects: 73
Study 31885300 — intervention group
Group type: COMPARATOR
Intervention: Wet dressing therapy combined with silver sulfadiazine
Number of subjects: 73
Study 31007001 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil combined with flurbiprofen axetil (SF group)
Number of subjects: 140
Study 31007001 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (S group)
Number of subjects: 140
Study 27651354 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with different exercises (three different exercises performed three times in two training sessions)
Number of subjects: 60
Study 27651354 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with different exercises
Number of subjects: 60
Study 25128910 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET on Day 3
Number of subjects: 199
Study 25128910 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET on Day 5
Number of subjects: 199
Study 25128910 — intervention group
Group type: EXPERIMENTAL
Intervention: eDET on Day 3
Number of subjects: 199
Study 25128910 — intervention group
Group type: EXPERIMENTAL
Intervention: eDET on Day 5
Number of subjects: 199
Study 25128910 — intervention group
Group type: COMPARATOR
Intervention: eSET
Number of subjects: 199
Study 25128910 — intervention group
Group type: COMPARATOR
Intervention: eDET
Number of subjects: 199
Study 23440713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment
Number of subjects: 5
Study 23440713 — intervention group
Group type: EXPERIMENTAL
Intervention: PWS post-PDL
Number of subjects: 5
Study 23440713 — intervention group
Group type: COMPARATOR
Intervention: Normal skin (N)
Number of subjects: 5
Study 23440713 — intervention group
Group type: COMPARATOR
Intervention: Untreated PWS (PWS)
Number of subjects: 5
Study 22093121 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching in addition to usual physiotherapy care
Number of subjects: 30
Study 22093121 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy alone
Number of subjects: 30
Study 19750263 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra parenteral fluid therapy
Number of subjects: 100
Study 19750263 — intervention group
Group type: COMPARATOR
Intervention: Breast milk (Control group)
Number of subjects: 100
Study 16469617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25, 50, or 100 mg)
Number of subjects: 256
Study 16469617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 15302102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 848
Study 15302102 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine plus verapamil
Number of subjects: 848
Study 15302102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 848
Study 11096147 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased erythropoietin (Epo) at Hb levels falling below 10.5 g/dl (group A)
Number of subjects: 447
Study 11096147 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased erythropoietin (Epo) at Hb levels falling below 11.5 g/dl (group B)
Number of subjects: 447
Study 11096147 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in Epo dose at Hb levels above 12.0 g/dl (group C)
Number of subjects: 447
Study 9415569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg once a day from day 1 to day 30, then 6 mg/kg once a day, Monday through Friday, until day 100)
Number of subjects: 47
Study 9415569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (less than 7 weeks, mean duration 3 weeks)
Number of subjects: 47
Study 9415569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (100 days prophylaxis)
Number of subjects: 47
Study 9415569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (long-term use)
Number of subjects: 47
Study 8347114 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety mood induction procedure (MIP)
Number of subjects: 0
Study 8347114 — intervention group
Group type: COMPARATOR
Intervention: Relaxation mood induction procedure (MIP)
Number of subjects: 0
Study 2426669 — intervention group
Group type: EXPERIMENTAL
Intervention: VDD pacing (back‐up rate 40-50 bpm, upper rate 125-150 bpm)
Number of subjects: 44
Study 2426669 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing (70 bpm)
Number of subjects: 44
Study 31375873 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant transobturator tape (TOT) with anterior colporrhaphy
Number of subjects: 164
Study 31375873 — intervention group
Group type: COMPARATOR
Intervention: Subvesical transobturator mesh (TOM)
Number of subjects: 164
Study 28946532 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue mobilization (STM) three times a week
Number of subjects: 29
Study 28946532 — intervention group
Group type: COMPARATOR
Intervention: Baseline home program (positioning, handling strategies, stretching and strengthening exercises, environmental adaptations)
Number of subjects: 29
Study 27453226 — intervention group
Group type: EXPERIMENTAL
Intervention: de qi group
Number of subjects: 0
Study 27453226 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study 25556937 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized screening (PSA testing every 2 years)
Number of subjects: 10000
Study 25556937 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic PSA testing
Number of subjects: 10000
Study 25556937 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized screening (biennial)
Number of subjects: 10000
Study 25556937 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized biennial screening
Number of subjects: 10000
Study 25556937 — intervention group
Group type: COMPARATOR
Intervention: Opportunistic screening
Number of subjects: 10000
Study 24359716 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Lines (HL) intervention
Number of subjects: 179
Study 24359716 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Lines intervention plus in-house monitoring (HLM)
Number of subjects: 179
Study 24359716 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 179
Study 20537281 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofilm-positive patients
Number of subjects: 51
Study 20537281 — intervention group
Group type: COMPARATOR
Intervention: Biofilm-negative patients
Number of subjects: 51
Study 19052242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt table with integrated stepping device
Number of subjects: 9
Study 19052242 — intervention group
Group type: COMPARATOR
Intervention: Conventional tilt table
Number of subjects: 9
Study 15883689 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CA)
Number of subjects: 0
Study 15883689 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty with stenting (CAS)
Number of subjects: 0
Study 12913723 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 421
Study 12913723 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 421
Study 12913723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 10099751 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-held group
Number of subjects: 150
Study 10099751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 10099751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) 7 mg/kg, Cyclophosphamide (CY) 50 mg/kg, Total-body irradiation (TBI) 12 Gy
Number of subjects: 31
Study 8558201 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cyclophosphamide (CY) 120 mg/kg and TBI (historical control)
Number of subjects: 31
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (BU) / Cyclophosphamide (CY) / Total-body irradiation (TBI)
Number of subjects: 31
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA genotypically matched marrow
Number of subjects: 31
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: All other marrow sources
Number of subjects: 31
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: RAEB-T
Number of subjects: 31
Study 8558201 — intervention group
Group type: EXPERIMENTAL
Intervention: RAEB and CMML
Number of subjects: 31
Study 1805277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 16
Study 1805277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6337363 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating good prognosis (total serum protein >= 6 g%, SGOT <= 40 mU/ml, total serum bilirubin <= 0.6 mg%)
Number of subjects: 0
Study 6337363 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating good prognosis
Number of subjects: 0
Study 6337363 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective laboratory tests indicating poor prognosis (presence of liver metastases)
Number of subjects: 0
Study 30206071 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded independent central review
Number of subjects: 45688
Study 30206071 — intervention group
Group type: COMPARATOR
Intervention: Local assessment
Number of subjects: 45688
Study 27871576 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (effect site concentration of 4 ng/mL)
Number of subjects: 120
Study 27871576 — intervention group
Group type: COMPARATOR
Intervention: Low-dose remifentanil (effect site concentration of 1 ng/mL)
Number of subjects: 120
Study 27871576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen (800 mg)
Number of subjects: 120
Study 24818763 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450, ritonavir, ombitasvir, and dasabuvir with ribavirin (group 1)
Number of subjects: 179
Study 24818763 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450, ritonavir, ombitasvir, and dasabuvir without ribavirin (group 2)
Number of subjects: 179
Study 24818763 — intervention group
Group type: COMPARATOR
Intervention: Comparison to telaprevir, peginterferon, and ribavirin
Number of subjects: 179
Study 23339698 — intervention group
Group type: EXPERIMENTAL
Intervention: Calluna vulgaris (Cv) + UVB irradiated
Number of subjects: 50
Study 23339698 — intervention group
Group type: COMPARATOR
Intervention: UVB irradiated
Number of subjects: 50
Study 23339698 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 23339698 — intervention group
Group type: EXPERIMENTAL
Intervention: Cv + vehicle + UVB irradiated
Number of subjects: 50
Study 23339698 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study 20361466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to standard chemotherapy regimens
Number of subjects: 0
Study 20361466 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based therapy
Number of subjects: 0
Study 20361466 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies
Number of subjects: 0
Study 18234327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored and targeted print-based PA interventions
Number of subjects: 280
Study 18234327 — intervention group
Group type: COMPARATOR
Intervention: Wellness/control condition
Number of subjects: 280
Study 15755830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g containing approximately 500 mg polyphenols)
Number of subjects: 15
Study 12715224 — intervention group
Group type: EXPERIMENTAL
Intervention: Noh's operation
Number of subjects: 90
Study 12715224 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y operation
Number of subjects: 90
Study 10758046 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 19
Study 10758046 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19
Study 10758046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 19
Study 8666447 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough titanium abutments
Number of subjects: 6
Study 8666447 — intervention group
Group type: COMPARATOR
Intervention: Smoother titanium abutments
Number of subjects: 6
Study 1602637 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐BMIPP
Number of subjects: 587
Study 3933604 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon therapy
Number of subjects: 108
Study 3933604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 15 MeV neutrons (LDN)
Number of subjects: 108
Study 3933604 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 15 MeV neutrons (HDN)
Number of subjects: 108
Study 3933604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of photon and neutron therapy
Number of subjects: 108
Study 3933604 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 31184024 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant complex (Androdoz) for 3 months
Number of subjects: 80
Study 31184024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy)
Number of subjects: 80
Study 30235745 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 60
Study 30235745 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 60
Study 26648173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Number of subjects: 100
Study 26648173 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 100
Study 24817601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral imatinib at doses ranging between 300 and 800 mg
Number of subjects: 61
Study 22335737 — intervention group
Group type: EXPERIMENTAL
Intervention: Semuloparin 20 mg once daily
Number of subjects: 3212
Study 22335737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3212
Study 20701468 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein concentration
Number of subjects: 255
Study 20701468 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in C-reactive protein concentration over gestation
Number of subjects: 255
Study 20701468 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline C-reactive protein
Number of subjects: 255
Study 17401042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with lower anxiety
Number of subjects: 0
Study 17401042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with higher anxiety
Number of subjects: 0
Study 17401042 — intervention group
Group type: COMPARATOR
Intervention: Placebo with lower anxiety
Number of subjects: 0
Study 17401042 — intervention group
Group type: COMPARATOR
Intervention: Placebo with higher anxiety
Number of subjects: 0
Study 16336365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-and-knees positioning for at least 30 minutes over a 1-hour period during labor
Number of subjects: 147
Study 16336365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-and-knees positioning
Number of subjects: 147
Study 16336365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hands-and-knees positioning)
Number of subjects: 147
Study 10840425 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (neodymium:YAG noncontact visual prostate ablation)
Number of subjects: 82
Study 10840425 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatic resection
Number of subjects: 82
Study 9356557 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal therapy among patients living with family
Number of subjects: 151
Study 9356557 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal therapy among patients living independently
Number of subjects: 151
Study 9356557 — intervention group
Group type: COMPARATOR
Intervention: Family and supportive therapies among patients living with family
Number of subjects: 151
Study 9356557 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy among patients living independently
Number of subjects: 151
Study 8457085 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (oral antiplatelet agent)
Number of subjects: 123
Study 8457085 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 123
Study 2880341 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 14
Study 2880341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2880341 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 14
Study 2880341 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 14
Study 30033790 — intervention group
Group type: EXPERIMENTAL
Intervention: LectureKeepr (LK) - audio lecture content before class
Number of subjects: 100